FL

Forge Life Science Partners

Description

Forge Life Science Partners is an investment firm.

Investor Profile

Forge Life Science Partners has made 5 investments, with 2 in the past 12 months and 20% as lead.

Stage Focus

  • Series A (40%)
  • Series C (20%)
  • Series B (20%)
  • Post Ipo Equity (20%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Oncology
  • Product Research
  • Therapeutics
  • Life Science
  • Medical
  • Health Care
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Forge Life Science Partners frequently co-invest with?

Abingworth
Europe, England, United Kingdom, London
Co-Investments: 1
Nextech Invest
Europe, Zurich, Switzerland, Zürich
Co-Investments: 2
Altitude Life Science Ventures
North America, Colorado, United States, Durango
Co-Investments: 1
5AM Ventures
North America, California, United States, Menlo Park
Co-Investments: 1
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 1
Casdin Capital
North America, New York, United States, New York
Co-Investments: 2
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 2
CH
North America, New York, United States, New York
Co-Investments: 1
Avego Management
North America, Georgia, United States, Alpharetta
Co-Investments: 1
Andreessen Horowitz
North America, California, United States, Menlo Park
Co-Investments: 2

Which angels does Forge Life Science Partners often collaborate with?

NL
North America, Massachusetts, United States, Cambridge
Shared Deals: 1

What are some of recent deals done by Forge Life Science Partners?

Aclaris Therapeutics

Malvern, Pennsylvania, United States

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

BiotechnologyPharmaceuticalTherapeutics
Post Ipo EquityNov 18, 2024
Amount Raised: $80,000,000
Idrx

Plymouth, Massachusetts, United States

Idrx is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment.

BiotechnologyLife ScienceOncologyProduct Research
Series BAug 7, 2024
Amount Raised: $120,000,000
OnCusp Therapeutics

New York, New York, United States

OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.

BiotechnologyHealth CareOncologyPharmaceuticalProduct Research
Series AJan 4, 2024
Amount Raised: $100,000,000
Escient Pharmaceuticals

San Diego, California, United States

Escient Pharmaceuticals is a privately-held biotechnology company focusing on the advancement of G Protein-Coupled Receptor targeted drugs.

BiotechnologyMedicalPharmaceuticalTherapeutics
Series CNov 28, 2022
Amount Raised: $120,000,000
Idrx

Plymouth, Massachusetts, United States

Idrx is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment.

BiotechnologyLife ScienceOncologyProduct Research
Series AAug 2, 2022
Amount Raised: $122,000,000